1. |
Antifungal resistance discussed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Tacrolimus ointment cost effective in atopic dermatitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Triflusal cost saving in the treatment of acute MI |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Cycloserine improves negative symptoms of schizophrenia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Enfuvirtide: turning the tide of drug resistance in HIV? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 7-8
Charles Bankhead,
Preview
|
|
摘要:
Highly active antiretroviral therapy (HAART) can result in long-term viral suppression and prolonged survival in patients with HIV infection. However, treatment for HIV infection is currently limited to three classes of drugs; nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors. Patients who experience virological failure to agents in one or more of these classes quickly exhaust their therapeutic options. As a result, considerable optimism has surrounded the development of enfuvirtide [T-20], the first member of a new therapeutic class, the HIV fusion inhibitors. The efficacy and tolerability of enfuvirtide were demonstrated in two phase II studies presented at the 9th Conference on Retroviruses and Opportunistic Infections [Seattle, US; February 2002]. The first, the T20-206 study, showed that enfuvirtide was effective in reducing viral loads and increasing CD4+ cell counts when used in combination with other antiretroviral agents in patients without extensive prior treatment experience and with less advanced disease.1Another study, T20-208, compared two different formulations of enfuvirtide in heavily pretreated patients.2
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Epirubicin + docetaxel + G-CSF effective in breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
LIFE study shows superiority of losartan |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 11-13
Ed Susman,
Preview
|
|
摘要:
Although they have comparable effects on blood pressure (BP), the angiotensin II receptor antagonist, losartan ['Cozaar'] is superior to atenolol in reducing the combined risk of stroke, myocardial infarction (MI) and cardiovascular-related mortality in patients with hypertension who have left ventricular hypertrophy (LVH), according to results from the landmark Losartan Intervention For Endpoint reduction (LIFE) study presented at the 51st Annual Scientific Sessions of the American College of Cardiology (ACC) [Atlanta, US; March 2002]; these results have subsequently been published in theLancet.1In the LIFE study, one of the largest clinical trials ever conducted in patients with hypertension, losartan reduced the combined risk of death, MI and stroke by 13%, and decreased the risks of stroke and new-onset diabetes mellitus by 25% each, compared with atenolol. Furthermore, analysis of results from a subgroup of patients who had diabetes mellitus at the time of enrolment showed that significant benefits were also achieved with losartan in this population.2Losartan is the first agent to clearly demonstrate superior efficacy to one of the 'gold standard' treatments for hypertension.'This study will have important implications for clinical practice',predicted the study's principal investigator, Dr Björn Dahlöf from Ostra University Hospital, Goteborg, Sweden.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Nesiritide superior to nitroglycerin in decompensated CHF |
|
Inpharma Weekly,
Volume &NA;,
Issue 1332,
2002,
Page 13-13
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|